The heavy accumulation by mega-passive managers (T. Rowe, Goldman, Vanguard) suggests a fundamental re-rating thesis, likely tied to Cullinan's oncology pipeline progress. However, the near-full exits by Point72 and Marshall Wace — both sophisticated event-driven shops — warrant monitoring for any negative catalyst that may have prompted their departure. Watch for upcoming clinical data readouts or partnership announcements that could explain the divergence.
Executive Summary
CGEM saw strong institutional accumulation in Q2 2026, with 26 buyers adding $68.3M in net new holdings (led by T. Rowe Price, Goldman Sachs, and Vanguard) while 13 sellers reduced positions by $29.6M (notably Point72 and Marshall Wace exiting near-fully). The net buying of $38.7M suggests broad institutional conviction in Cullinan's pipeline prospects, though the near-exit by two prominent quant/event-driven funds introduces a cautionary note.
Key Financial Metrics
Institutional Positions
Net institutional flow: $38.7M
▲ Buyers (26)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| T. Rowe Price | ADD | +88.5% | $69.7M | $40.8M |
| Goldman Sachs | DOUBLED | +119.9% | $18.2M | $11.8M |
| Vanguard Portfolio Management | ADD | +33.7% | $13.5M | $5.6M |
| Fidelity | DOUBLED | +3220.2% | $4.4M | $4.3M |
▼ Sellers (13)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Marshall Wace | NEAR_EXIT | -93.7% | $14.9M | -$13.7M |
| Point72 | NEAR_EXIT | -91.7% | $12.9M | -$11.5M |
| Nuveen | TRIM | -41.4% | $11.4M | -$2.9M |
Key Facts
- 26 institutional buyers added $68.3M in net new holdings; 13 sellers reduced by $29.6M
- T. Rowe Price added 1.80M shares (+88.5%), now holding $69.7M — the largest buyer by far
- Goldman Sachs doubled its position (+119.9%), adding $11.8M to reach $18.2M
- Point72 cut 91.7% of its stake (from $12.9M to $1.4M), near-exit
- Marshall Wace cut 93.7% of its stake (from $14.9M to $1.2M), near-exit
- Fidelity more than 30x'd its tiny position (from $103K to $4.4M), but from a negligible base
- Net aggregate institutional inflow of ~$38.7M
Financial Impact
Net institutional inflow of ~$38.7M in Q2 2026, with $68.3M in buying vs $29.6M in selling
Risk Factors
- Two prominent quant/event-driven funds (Point72, Marshall Wace) nearly fully exited, suggesting a potential negative catalyst or thesis change
- 13F data is 45 days stale; positions may have already been adjusted post-quarter-end
- Biotech pipeline risk: clinical trial failures could reverse the accumulation thesis
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-CGEM-2026-Q2 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | Press Release | $15.51 | awaiting T+60 | — | — |
Sep 24, 2026 4w ago | 8-K | $15.44 | awaiting T+60 | — | — |
Sep 24, 2026 4w ago | Press Release | $15.44 | awaiting T+60 | — | — |
Sep 22, 2026 5w ago | Institutional Cluster | $21.67 | awaiting T+60 | — | — |
Sep 14, 2026 6w ago | 8-K | $20.40 | awaiting T+60 | — | — |
Aug 6, 2026 11w ago | 8-K | $17.95 | awaiting T+60 | — | — |
Jun 11, 2026 19w ago | Institutional Cluster | $12.98 $21.69 | ▲ +67.10% | ▲ +63.28% | — |
Jun 10, 2026 19w ago | Press Release | $12.05 $22.09 | ▲ +83.32% | ▲ +77.15% | — |
Jun 8, 2026 20w ago | 8-K | $13.28 $22.33 | ▲ +68.15% | ▲ +64.64% | — |
May 19, 2026 23w ago | Press Release | $14.18 $19.64 | ▲ +38.55% | ▲ +32.26% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers